2016

• business2016/12/19

  AskAt Inc. Announces EP4 Antagonist Oncology and Auto-Immune Diseases Partnership with Ningbo Tai Kang Medical Technology Co., Ltd.

  AskAt Inc. and Ningbo Tai Kang Medical Technology Co., Ltd in China closed a license agreement on EP4 Antagonist [AAT-007] for Oncology and Auto-Immune Diseases in China.

• patent2016/12/02

  Ocular Diseases Use Patent for COX-2 Inhibitor (AAT-076) Approved in US

  AskAt received a notice of allowance dated December 2, 2016 from the United States Patent and Trademark Office (USPTO) in connection with the Application No. 14/776,048, a use patent of COX-2 inhibitor (AAT-076) for ocular diseases.
  

• patent2016/10/28

  Formulation Patent for COX-2 Inhibitor (AAT-076) Approved in Japan

  AskAt received a notice of allowance dated October 28, 2016 from the Japanese Patent Office in connection with the Application No. 2013-539678, a formulation patent for its COX-2 inhibitor (AAT-076).
  

• patent2016/09/20

  Formulation Patent for COX-2 Inhibitor (AAT-076) Approved in US

  AskAt obtained a patent dated September 20, 2016 from the United States Patent and Trademark Office (USPTO) in connection with the Application No. 14/351,190, a formulation patent for its COX-2 inhibitor (AAT-076).
  

• patent2016/08/30

  Dementia Use Patent for 5-HT4 Receptor Agonist (AAT-009) Approved in Mexico

  AskAt received a notice of allowance dated August 30, 2016 from the Instituto Mexicano de la Propiedad Industrial (IMPI) in connection with the Application No. MX/a/2012/009211, a use patent of 5-HT4 receptor agonist for dementia.
  

• patent2016/08/17

  Treatment of Cancer Use Patent for EP4 antagonist Approved in China

  AskAt received a notice of allowance dated August 17, 2016 from State Intellectual Property Office of the P.R.C. (SIPO) in connection with the Application No. 201080017743.X, a use patent of EP4 receptor antagonist for the treatment of Cancer.
  

• patent2016/07/26

  US Patent Office Granted AskAt a Salt & Crystal Forms Patent of COX-2 Inhibitor (AAT-076)

  AskAt, Inc. announced today that AskAt received a notice of allowance dated July 17, 2016 from the United States Patent and Trademark Office (USPTO) in connection with the Application No. 14/655,175, a salt and crystal forms patent for its COX II Inhibitor (AAT-076).
  

• company2016/07/25

  Article published in Nikkan Kogyo Shinbun

  An article about AskAt was published on the column of "Japanese future company - Create Next Millennium” in Nikkan Kogyo Shinbun (Newspaper) issued on July 25, 2016.

• patent2016/06/03

  Autoimmune disease Use Patent for EP4 antagonist Approved in Mexico

  AskAt received a notice of allowance dated June 3, 2016 from the Instituto Mexicano de la Propiedad Industrial (IMPI) in connection with the Application No. Mx/a/2012/009503, a use patent of EP4 antagonist.
  

• patent2016/05/31

  Autoimmune disease Use Patent for EP4 antagonist Approved in US

  AskAt received a notice of allowance dated May 31, 2016 from the United States Patent and Trademark Office (USPTO) in connection with the Application No. 13/580,323, a use patent of EP4 antagonist.
  

• company2016/05/18

  Article published in Chubu Keizai Shinbun

  An article about AskAt was published in Chubu Keizai Shinbun (The Mid-Japan Economist) issued on May 18, 2016

• business2016/04/26

  Aratana, Elanco Announce Global Strategic Collaboration

  On April 25, 2016, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), announced that Elanco has licensed animal health rights to Aratana's Galliprant® (grapiprant／RQ-00000007／AT-001／AAT-007), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.
  
  

• patent2016/04/19

  Autoimmune disease Use Patent for EP4 antagonist Approved in EU

  AskAt Inc. announced that EU patent office granted AskAt a use patent of EP4 receptor antagonist in EU (application number: 11744440.6).

• patent2016/04/06

  AskAt received an Allowance for 5-HT4 receptor agonist use patent in Japan

  AskAt Inc. announced that the company received an allowance for 5-HT4 receptor agonist use patent in Japan (Application Number: 2012-536636). This use patent allowance grants AskAt the right to develop 5-HT4 receptor agonist (AAT-009) to be used as a drug for Dementia.

• business2016/03/22

  Aratana Therapeutics granted First U.S. FDA Approval with AskAt Compound, A Targeted Therapeutic Intended for Control of Pain and Inflammation in Dogs with Osteoarthritis

  KANSAS CITY, Kan., March 21, 2016 Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced the Food and Drug Administration's Center for Veterinary Medicine (CVM) approved GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs. Galliprant is expected to be available to veterinarians in fall 2016.

• company2016/03/18

  AskAt completed an 50,000,000 yen financing from Nagoya Small and Medium Business Investment & Consultation Co.,Ltd

  AskAt Inc. announced today that it has completed an 50,000,000 yen financing. The financing was made by Nagoya Small and Medium Business Investment & Consultation Co.,Ltd (SBIC Central Japan)

• business2016/02/18

  Aratana Therapeutics Filed for European Medicines Agency (EMA) Approval with AskAt Compound, a Targeted Therapeutic Intended for Control of Pain and Inflammation in Dogs with Osteoarthritis

  February 17, 2016 - Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced that it filed a Marketing Authorization Application with the European Medicines Agency (EMA) for EP4 antagonist (Galliprant®/grapiprant/ RQ-00000007/AT-001, hereinafter called "Galliprant")
  

• patent2016/02/09

  Treatment of Cancer Use Patent for EP4 antagonist Approved in Canada

  AskAt received a notice of allowance dated February 9, 2016 from Canadian Intellectual Property Office in connection with the Application No. 2,754,702, a use patent of EP4 receptor antagonist for the treatment of Cancer.
  

• business2016/01/25

  Aratana Therapeutics Files for First U.S. FDA Approval with AskAt Compound, A Targeted Therapeutic Intended for Control of Pain and Inflammation in Dogs with Osteoarthritis

  January 25, 2016 - Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced today that it filed an administrative New Animal Drug Application (NADA) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for Galliprant® for control of pain and inflammation in dogs with osteoarthritis. The Animal Drug User Fee Act (ADUFA) date for approval is set for March 25.

• business2016/01/01

  AskAt Inc. Announces EP4 Antagonist and COX-2 Inhibitor Pain Partnership with RMX Pharmaceutical Technology Co., Ltd.

  January 1, 2016 – AskAt Inc. (AskAt), headquartered in Nagoya, Japan, today announced license agreements with RMX Pharmaceutical Technology Co., Ltd. (RMX), headquartered in Hangzhou, Zheijiang Province, People's Republic of China (China), granting RMX exclusive rights to develop, manufacture and commercialize AskAt’s EP4 Antagonist [AAT-007] and COX-2 Inhibitor [AAT-076] in China for Pain.